Medipure News

MEDIPURE EXPANDS TO CROATIA

Vancouver, BC – Medipure Holdings Inc. is taking another step to advance its research and development by creating a subsidiary, Medipure d.o.o., in Croatia.

The Croatian R&D facility will focus on clinical trials and pharmacology. Along with full analytical labs, this site will house a GMP facility allowing the Company to produce drugs in compliance with the European regulatory standards necessary to support clinical trials on the road to regulatory approvals and commercialization.

MEDIPURE EXPANDS TO INDIA

Vancouver, BC – Medipure Holdings Inc. has taken the next step to advance its research and development by creating a subsidiary, Medipure LifeSciences India (MLSI) Pvt Ltd.

MEDIPURE PHARMACEUTICALS BURNABY LAB GRAND OPENING

We are so excited to have recently opened a 3,750 square foot research lab on the BCIT campus in Burnaby. This lab is crucial in our quest to help patients worldwide.

As a company we are committed to developing economical non-addictive prescription medications derived from specific cannabinoid molecules. Our core products target key disease areas including pain management, mood disorders/anxiety, nausea, appetite, oncology, arthritis and dermatology. This lab is our first step in fulfilling our dreams.

MEDIPURE PHARMACEUTICALS ROUNDS OUT SUCCESSFUL 2017: YEAR END HIGHLIGHTS

Medipure Pharmaceuticals has established itself as a biopharmaceutical incubator committed to discovering and developing proprietary cannabinoid-derived prescription medications through state of the art research and development. Medipure is wrapping up an extremely successful 2017 with highlights that include achieving new research milestones, developing new strategic relationships, adding renowned industry leaders to the team, and much more.

MEDIPURE PHARMACEUTICALS INC. ANNOUNCES EXPANSION OF CORPORATE OFFICES AND BURNABY LABS TO FURTHER RESEARCH MEDICAL BENEFITS OF CANNABINOIDS AT THE MOLECULAR LEVEL

Vancouver, BC – December 6, 2017 -

Medipure Pharmaceuticals, a biopharmaceutical incubator committed to discovering and developing proprietary cannabinoid-derived prescription medications, today announced that they are further expanding both their corporate offices in Vancouver and their research labs in Burnaby, B.C., to enhance the Company’s research aimed at developing cannabinoid-derived molecules into non-addictive pharmaceutical drugs.

Pages